A detailed history of Nisa Investment Advisors, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 345 shares of ALLK stock, worth $238. This represents 0.0% of its overall portfolio holdings.

Number of Shares
345
Previous 235 46.81%
Holding current value
$238
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$1.0 - $1.45 $110 - $159
110 Added 46.81%
345 $0
Q1 2024

May 01, 2024

SELL
$1.02 - $3.23 $40 - $129
-40 Reduced 14.55%
235 $0
Q4 2023

Jan 25, 2024

BUY
$1.72 - $3.18 $68 - $127
40 Added 17.02%
275 $0
Q3 2023

Nov 02, 2023

SELL
$2.13 - $5.55 $159 - $416
-75 Reduced 24.19%
235 $0
Q2 2023

Aug 11, 2023

BUY
$3.6 - $5.25 $270 - $393
75 Added 31.91%
310 $1,000
Q2 2022

Aug 03, 2022

SELL
$2.6 - $6.14 $6,240 - $14,736
-2,400 Reduced 91.08%
235 $1,000
Q1 2022

Apr 29, 2022

BUY
$5.08 - $9.81 $3,972 - $7,671
782 Added 42.2%
2,635 $15,000
Q4 2021

Feb 03, 2022

SELL
$8.55 - $111.89 $3,266 - $42,741
-382 Reduced 17.09%
1,853 $13,000
Q3 2021

Oct 18, 2021

BUY
$76.53 - $110.43 $95,662 - $138,037
1,250 Added 126.9%
2,235 $237,000
Q4 2020

Jan 25, 2021

BUY
$79.58 - $152.45 $7,958 - $15,244
100 Added 11.3%
985 $138,000
Q3 2020

Oct 20, 2020

BUY
$66.43 - $90.99 $8,702 - $11,919
131 Added 17.37%
885 $72,000
Q2 2020

Jul 27, 2020

SELL
$44.04 - $80.69 $7,134 - $13,071
-162 Reduced 17.69%
754 $54,000
Q1 2020

Apr 17, 2020

BUY
$44.49 - $93.39 $2,224 - $4,669
50 Added 5.77%
916 $41,000
Q4 2019

Jan 17, 2020

BUY
$66.49 - $137.73 $57,580 - $119,274
866 New
866 $83,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $58.5M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.